Articles tagged "Cytomeglovirus"

2022 American Transplant Congress
The Effect of Late-Onset Cytomegalovirus Infection on the Outcome of Renal Allograft in Patients with Delayed Graft Function
M. Rahimi Shahmirzadi¹, M. Silverman¹, L. Gunaratnam², A. Jevnikar², A. A. House², S. Hosseini-Moghaddam³
¹Infectious Diseases Care Program, St. Joseph's Health Care London, London, ON, Canada, ²London Health Sciences Centre, London, ON, Canada, ³St. Joseph's Health Care London, London, ON, Canada
*Purpose: Delayed graft function (DGF) has been reported to increase the risk of renal allograft loss. The role of late-onset Cytomegalovirus infection in the association…
2022 American Transplant Congress
Analysis of Induction Dose and Incidence of CMV Viremia in High Risk (HR; D+/R-) Renal Transplant Recipients
K. Shimko, M. Pittappilly, R. Chowdhury, H. Karimi, C. Puttarajappa, M. Wijkstrom, R. Mehta
University of Pittsburgh Medical Center, Pittsburgh, PA
*Purpose: Depleting induction puts patients at risk of opportunistic infections. Our protocol aims for 5-6mg/kg cumulative dose of antithymocyte globulin(ATG) divided over 4 doses. It…
2022 American Transplant Congress
Preemptive  Therapy for Cytomegalovirus (CMV) Disease Prevention in High-Risk CMV Donor Seropositive Recipient Seronegative (D+/R-) Liver Transplant Recipients in a Real-World Setting 
K. M. Doss¹, C. Kling¹, M. R. Heldman¹, N. Singh², M. Wagener³, C. E. Fisher¹, A. Limaye¹
¹University of Washington, Seattle, WA, ²University of Pittsburgh, PIttsburgh, PA, ³University of Pittsburgh, Pittsburgh, PA
*Purpose:  Preemptive therapy  (PET)  has  demonstrated superiority to antiviral prophylaxis  for  prevention of  cytomegalovirus (CMV)  disease  in  CMV  donor seropositive/recipient seronegative (D+R-)  liver transplant recipients …
2022 American Transplant Congress
Multidimensional Immunological Profiling of CMV Dnaemia in Kidney Transplant Recipients
H. Pickering¹, S. Sen², R. S. Ahn², Z. Qian¹, G. Sunga¹, M. LLamas¹, A. Hoffmann¹, M. Deng¹, S. Bunnapradist³, J. Schaenman⁴, D. W. Gjertson¹, M. Rossetti¹, E. Reed⁵
¹UCLA, Los Angeles, CA, ²University of California Los Angeles, Los Angeles, CA, ³David Geffen School of Medicine, Los Angeles, CA, ⁴David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁵Univ of California LA, Los Angeles, CA
*Purpose: Human cytomegalovirus (CMV) infects over half the global population, leading to a mostly asymptomatic but lifelong infection. Primary infection or reactivation in immunocompromised individuals…
2022 American Transplant Congress
Incidence of Viral Infections in Kidney Transplant Recipients Using Reduced Induction and Steroid Free Maintenance Immunosuppression
P. Dunton, L. Von Stein, H. Winters, A. Schenk, T. Pesavento, R. M. Smith, K. Schnelle
Ohio State University Wexner Medical Center, Columbus, OH
*Purpose: Viral infections (VI) commonly occur in the post-transplant period and higher cumulative doses of rATG have been correlated with higher rates of infection. However,…
2022 American Transplant Congress
Single Dose Alemtuzemab Provides Comparable Rejection Free and Infection Free Survival Compared to Double Dose Alemtuzumab. In Comparison to Alemtuzemab, Basiliximab Has Superior Infection Free Graft Survival. Results from a Steroid Sparing Transplant Group
H. Sharma, A. Odugoudar, B. Devkaran, A. Rao, A. El-Bakry, T. Gunawardhane, D. Ridgway, M. Howse, S. Mehra
Department of Transplant Surgery, Royal Liverpool University Hospital, Liverpool, United Kingdom
*Purpose: The present study investigated the short-term biopsy-proven acute rejection rates and viral infection rates amongst our protocol of single-dose Alemtuzemab (Cohort 1) versus double…
2022 American Transplant Congress
Cytomegalovirus Prevention in Kidney and Pancreas Transplant Recipients: A Successful Pharmacist-Led Multidisciplinary Approach
J. Geyston, J. Dann, A. Doyle, A. Agarwal, K. Brayman, C. Shoemaker, C. Lester, S. Rao
University of Virginia Health, Charlottesville, VA
*Purpose: In response to high cytomegalovirus (CMV) infection and increasing ganciclovir (GCV)-resistance rate, a pharmacist-led multidisciplinary task force was created to manage CMV prophylaxis (ppx).…
2022 American Transplant Congress
Early versus Delayed Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients
A. Hutchins¹, M. Leick², M. Keck², J. S. McMullen²
¹Pharmacy, Houston Methodist Hospital, Houston, TX, ²Pharmacy, Nebraska Medicine, Omaha, NE
*Purpose: The purpose of this study is to determine the effect of delaying cytomegalovirus (CMV) prophylaxis to day of discharge or post-operative day (POD) 7…
2022 American Transplant Congress
De-Novo Belatacept Therapy is Associated with an Increased Risk of Invasive CMV Disease After Kidney Transplantation
G. Petrossian¹, J. Ortiz², K. Addonizio¹, A. Hsiao¹, L. Teixeira¹, N. Koizumi³, R. James³, S. Patel⁴, D. Conti², R. Plews²
¹Albany Medical Center, Albany, NY, ²Division of Renal and Pancreatic Transplant Services, Albany Medical Center, Albany, NY, ³George Mason University, Fairfax, VA, ⁴UMC Las Vegas, Las Vegas, NV
*Purpose: To compare the rate of CMV viremia and invasive disease in kidney transplantation patients with a de-novo belatacept (bela) regimen vs. a no-bela maintenance…
2021 American Transplant Congress
Cytomegalovirus (CMV) D+/R- Serostatus is Independently Associated with Mortality and Graft Loss After Liver Transplantation (LTx)
P. Vutien, J. Perkins, S. Biggins, J. Reyes, A. Limaye
Internal Medicine, University of Washington Medical Center, Seattle, WA
*Purpose: It is unknown if donor or recipient (D/R) CMV serostatus, in the era of CMV prophylactic and pre-emptive strategies, remains associated with clinical outcomes…